Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 15
Substance-Related Disorders 44 72
Substance Abuse Problem 72

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 44 D019966
NCIt 50 C16522
SNOMED-CT 68 26416006
UMLS 72 C0013146 C0236969 C0740858

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to depression and eating disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Acetylcholine and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 75 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 depression 33.4 SLC6A4 MAOA BDNF
2 eating disorder 32.8 SLC6A4 SLC6A3 NPY DRD2 COMT BDNF
3 borderline personality disorder 32.8 SLC6A4 MAOA HTR1B COMT BDNF
4 bipolar disorder 32.7 SLC6A4 SLC6A3 DRD3 DRD2 COMT BDNF
5 schizoaffective disorder 32.6 SLC6A4 PRL DRD3 DRD2 COMT BDNF
6 cocaine abuse 32.4 SLC6A4 SLC6A3 PRL DRD2 DBH BCHE
7 drug dependence 31.8 SLC6A4 DRD3 DRD2 BDNF
8 avoidant personality disorder 31.8 SLC6A4 MAOA
9 brain injury 31.7 DRD2 COMT BDNF
10 traumatic brain injury 31.7 DRD2 COMT BDNF
11 opiate dependence 31.7 SLC6A4 DRD3 DRD2
12 polysubstance abuse 31.5 DRD3 DRD2 COMT
13 alexithymia 31.3 SLC6A4 DRD2 COMT
14 post-traumatic stress disorder 31.2 SLC6A4 MAOA DRD2 COMT BDNF
15 tobacco addiction 31.2 SLC6A4 SLC6A3 MAOA DRD2 COMT
16 antisocial personality disorder 31.1 SLC6A4 SLC6A3 MAOA HTR1B DRD2 COMT
17 mental depression 31.1 SLC6A4 MAOA CYP2D6 COMT BDNF
18 anxiety 31.1 SLC6A4 NPY MAOA CYP2D6 COMT BDNF
19 panic disorder 31.1 SLC6A4 MAOA COMT
20 cocaine dependence 31.1 SLC6A4 SLC6A3 DRD3 DRD2 DBH
21 bipolar i disorder 31.0 SLC6A4 COMT BDNF
22 social phobia 30.9 SLC6A4 PRL MAOA DRD2
23 generalized anxiety disorder 30.9 SLC6A4 MAOA DRD2 COMT BDNF
24 pathological gambling 30.9 SLC6A4 SLC6A3 MAOA DRD4 DRD3 DRD2
25 schizophreniform disorder 30.9 PRL DRD2 COMT
26 phobic disorder 30.8 SLC6A4 MAOA COMT
27 movement disease 30.8 SLC6A3 DRD3 DRD2
28 alcoholic psychosis 30.8 SLC6A4 SLC6A3 DRD2
29 personality disorder 30.7 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD4
30 anorexia nervosa 30.7 SLC6A4 PRL NPY COMT BDNF
31 bulimia nervosa 30.7 SLC6A4 NPY HTR1B COMT BDNF
32 disease of mental health 30.7 SLC6A4 SLC6A3 MAOA DRD4 DRD3 DRD2
33 tardive dyskinesia 30.6 DRD3 DRD2 CYP2D6 COMT
34 conduct disorder 30.6 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
35 impulse control disorder 30.6 DRD4 DRD3 DRD2
36 postpartum depression 30.6 SLC6A4 PRL MAOA COMT BDNF
37 delusional disorder 30.6 DRD4 DRD3 DRD2 CYP2D6
38 heroin dependence 30.5 MIAT DRD4 DRD2 BDNF
39 premature ejaculation 30.5 SLC6A4 SLC6A3 HTR1B
40 endogenous depression 30.5 SLC6A4 NPY MAOA BDNF
41 atypical depressive disorder 30.4 SLC6A4 MAOA
42 mood disorder 30.3 SLC6A4 NPY MAOA HTR1B DRD4 DRD3
43 substance dependence 30.3 SLC6A4 SLC6A3 MAOA HTR1B DRD5 DRD4
44 psychotic disorder 30.2 SLC6A4 SLC6A3 PRL DRD4 DRD3 DRD2
45 oppositional defiant disorder 30.1 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
46 gilles de la tourette syndrome 30.1 SLC6A3 DRD5 DRD4 DRD2 DBH COMT
47 brunner syndrome 29.9 SLC6A4 MAOA HTR1B DBH COMT
48 alcohol dependence 29.8 SLC6A4 SLC6A3 NPY MAOA HTR1B GABRA2
49 paranoid schizophrenia 29.7 SLC6A4 MIAT MAOA COMT BDNF
50 schizophrenia 29.7 SLC6A4 SLC6A3 PRL NPY MIAT MAOA

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT CYBB DBH DRD2 DRD3
2 cardiovascular system MP:0005385 10.07 ABCB7 COMT CYBB DBH DRD2 DRD3
3 homeostasis/metabolism MP:0005376 10.06 ABCB7 BCHE BDNF COMT CYBB DBH
4 growth/size/body region MP:0005378 10 ABCB7 BDNF CYBB DBH DRD2 DRD3
5 endocrine/exocrine gland MP:0005379 9.97 BDNF COMT DBH DRD2 DRD5 HTR1B
6 adipose tissue MP:0005375 9.91 CYBB DBH DRD2 DRD3 HTR1B NPY
7 mortality/aging MP:0010768 9.77 ABCB7 BCHE BDNF CYBB DBH DRD2
8 nervous system MP:0003631 9.5 ABCB7 BDNF COMT CYBB DBH DRD2

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 510)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Lithium carbonate Approved Phase 4 554-13-2
7
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Desipramine Approved, Investigational Phase 4 50-47-5 2995
10
Memantine Approved, Investigational Phase 4 19982-08-2 4054
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Baclofen Approved Phase 4 1134-47-0 2284
13
Amantadine Approved Phase 4 768-94-5 2130
14
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
15
Histamine Approved, Investigational Phase 4 51-45-6 774
16
Ziprasidone Approved Phase 4 146939-27-7 60854
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
22
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
23
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
24
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
25
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
26
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
27
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
28
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
29
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
30
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
33
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
34
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
35
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
36
Cobicistat Approved Phase 4 1004316-88-4
37
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
38
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Desogestrel Approved Phase 4 54024-22-5 40973
41
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
42
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
43
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
44
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
45
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
46
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
47
Methadone Approved, Illicit Phase 4 76-99-3 4095
48
Clozapine Approved Phase 4 5786-21-0 2818
49
Morphine Approved, Investigational Phase 4 57-27-2 5288826
50
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 1954)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo
3 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
4 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
5 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
6 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One Unknown status NCT01825057 Phase 4
7 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
8 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
9 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
10 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
13 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
14 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
15 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
16 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
17 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
18 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
19 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
20 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
21 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
22 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
23 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
24 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
25 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
26 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
27 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
28 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
29 Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV Completed NCT01008280 Phase 4 baclofen;placebo
30 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
31 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
32 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
33 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
34 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
35 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
36 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
37 Effectiveness of Naltrexone in a Community Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
38 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
39 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
40 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
41 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
42 The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers Completed NCT01829516 Phase 4 Oxytocin;Placebo
43 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
44 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
45 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
46 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
47 Vilazodone for Separation Anxiety Disorder Completed NCT01999920 Phase 4 Vilazodone;Placebo
48 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4 SODAS MPH;Naltrexone
49 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
50 A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Desipramine
Desipramine Hydrochloride
Doxapram
Doxapram Hydrochloride
Mirtazapine

Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

41
Brain, Testes, Cortex, Liver, Heart, Spinal Cord, Prefrontal Cortex

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 23313)
# Title Authors PMID Year
1
Adolescent intermittent ethanol impairs behavioral flexibility in a rat foraging task in adulthood. 38
31319133 2019
2
Parenting stress: A novel mechanism of addiction vulnerability. 38
31193862 2019
3
Editorial for neurobiology of stress special issue on stress and substance abuse throughout development. 38
31198822 2019
4
Flourishing despite a cancer diagnosis: factors associated with complete mental health in a nationally-representative sample of cancer patients aged 50 years and older. 38
30130417 2019
5
Adverse childhood experiences and electronic cigarette use among young Australian women. 38
31251947 2019
6
MMPI-2-RF patterns after traumatic brain injury. 38
31219277 2019
7
Genes, Childhood Trauma, and Late Life Depressive Symptoms. 38
31288597 2019
8
Cannabidiol affects circadian clock core complex and its regulation in microglia cells. 38
30307084 2019
9
Self-reported adverse childhood experiences and quality of life among children in the two last grades of Dutch elementary education. 38
31344586 2019
10
Incidence of chronic pain 6 y after major trauma. 38
31012096 2019
11
Substance Abuse Disorder: Prenatal, Intrapartum and Postpartum Care. 38
31415268 2019
12
An Examination of Comorbid Psychiatric Disorders in Disordered Gamblers Versus Other Substance-Related Disorders. 38
30778813 2019
13
Generalization of appetitive conditioned responses. 38
31152454 2019
14
Adverse childhood experiences predict opioid relapse during treatment among rural adults. 38
31102882 2019
15
Severe maternal morbidity during delivery hospitalisation in a large international administrative database, 2008-2013: a retrospective cohort. 38
31100201 2019
16
The Role of Childhood Adversity in the Development of Gestational Diabetes. 38
31353162 2019
17
Building Mental Health Research Capacity in Kenya: A South - North Collaboration. 38
31403024 2019
18
A current re-examination of racial/ethnic disparities in the use of substance abuse treatment: Do disparities persist? 38
31352305 2019
19
On the behavioral economics of medication choice: A research story. 38
31181266 2019
20
Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways. 38
31373129 2019
21
A comparative evaluation of Korean MMPI-A and MMPI-A-RF Substance Abuse Scales. 38
31386196 2019
22
Identifying Barriers to the Treatmentof Chronic Hepatitis C Infection. 38
31422405 2019
23
Race, Poverty, and Mental Health Drive Colorectal Cancer Screening Disparities in the Veterans Health Administration. 38
31415338 2019
24
Individual short-acting opioids and the risk of opioid-related adverse events in adolescents. 38
31418512 2019
25
Predictors of Post-Discharge Suicide Attempt Among Veterans Receiving Specialized Intensive Treatment for Posttraumatic Stress Disorder. 38
31412170 2019
26
Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review. 38
30076092 2019
27
Subtle scales: An avenue for identification of prescription drug abuse. 38
30954396 2019
28
Effect of early maternal separation stress on attention, spatial learning and social interaction behaviour. 38
31154461 2019
29
The characteristics of internet-based venue sex-seeking and mobility among money boys in Tianjin, China. 38
31006956 2019
30
Peer specialists: Exploring the influence of program structure on their emerging role. 38
30407058 2019
31
Experience of maternal and paternal adversities in childhood as determinants of self-harm in adolescence and young adulthood. 38
31431474 2019
32
Association of status of acetylcholinesterase and ACHE gene 3' UTR variants (rs17228602, rs17228616) with drug addiction vulnerability in pakistani population. 38
31129131 2019
33
Factors Associated with Secondary Overtriage in Renal Trauma. 38
31029673 2019
34
Firearm Legislation Stringency and Firearm-Related Fatalities among Children in the US. 38
30928667 2019
35
Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost. 38
30543495 2019
36
Demographic, socioeconomic, and health correlates of unmet need for mental health treatment in the United States, 2002-16: evidence from the national surveys on drug use and health. 38
31382979 2019
37
ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan. 38
31385763 2019
38
Identifying and classifying opioid-related overdoses: A validation study. 38
31020755 2019
39
Nonoperative Management Prior to Hip Arthroscopy for Femoroacetabular Impingement Syndrome: An Investigation Into the Utilization and Content of Physical Therapy. 38
31092124 2019
40
Examining Predisposing Factors and Program Performance Indicators Associated With Program Completion: A Comparison of Opioid and Non-Opioid-Preferring Participants in Drug Court. 38
31366261 2019
41
Meta-analysis and systematic review for the treatment of perpetrators of intimate partner violence. 38
31415863 2019
42
A picture of the older homeless female veteran: A qualitative, case study analysis. 38
31280786 2019
43
Tools for Moving On: Adapting an Evidence-Based Housing Curriculum for Individuals Receiving Services in an Inpatient Psychiatric Setting to Prepare for Community Living. 38
30973612 2019
44
Identifying Distinct Latent Classes of Adverse Childhood Experiences Among US Children and Their Relationship with Childhood Internalizing Disorders. 38
30796680 2019
45
The religion variable in community health promotion and illness prevention. 38
31402789 2019
46
The Prevention of Drugged Driving: Needs, Barriers, and Self-Efficacy of Prevention Professionals. 38
31346838 2019
47
Should a Homeless Person Become a Deceased Organ Donor? 38
31381199 2019
48
Coevolution of Residues Provides Evidence of a Functional Heterodimer of 5-HT2AR and 5-HT2CR Involving Both Intracellular and Extracellular Domains. 38
31158438 2019
49
Teaching Basic Knowledge on Substance Use Disorders: the Impact of e-Learning on Health Professionals. 38
31395392 2019
50
Neurocognitive Complications of HIV Infection in Women: Insights from the WIHS Cohort. 38
31396894 2019

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 PRL NPY HTR1B GABRA2 DRD5 DRD4
2
Show member pathways
12.84 SLC6A4 SLC6A3 MAOA GABRA2 COMT BCHE
3
Show member pathways
12.82 SLC6A3 MAOA DRD5 DRD4 DRD3 DRD2
4
Show member pathways
12.64 DRD5 DRD4 DRD3 DRD2 BDNF
5 12.19 DRD5 DRD4 DRD3 DRD2
7 12.01 TF SLC6A4 MAOA BDNF
8 11.99 NPY HTR1B DRD5 DRD2 BDNF
9
Show member pathways
11.85 SLC6A3 MAOA DRD2 BDNF
10 11.82 SLC6A4 MAOA HTR1B CYP2D6
11
Show member pathways
11.77 DRD4 DRD3 DRD2
12
Show member pathways
11.4 HTR1B DRD5 DRD4 DRD3 DRD2
13
Show member pathways
11.09 SLC6A4 SLC6A3 MAOA DBH
14 11.06 SLC6A4 MAOA HTR1B
15 10.89 DRD5 DRD3 DRD2
16
Show member pathways
10.84 MAOA DBH COMT
17
Show member pathways
10.75 MAOA COMT
18 10.71 MAOA COMT
19
Show member pathways
10.44 SLC6A4 SLC6A3 MAOA COMT BCHE

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 SLC6A4 SLC6A3 HTR1B GABRA2 DRD5 DRD4
2 axon GO:0030424 9.83 SLC6A3 GABRA2 DRD2 COMT BDNF
3 endocytic vesicle GO:0030139 9.63 TF DRD3 DRD2
4 integral component of postsynaptic membrane GO:0099055 9.58 SLC6A4 SLC6A3 DRD2
5 integral component of presynaptic membrane GO:0099056 9.46 SLC6A4 SLC6A3 HTR1B DRD2
6 serotonergic synapse GO:0099154 9.32 SLC6A4 HTR1B
7 dendrite GO:0030425 9.17 HTR1B GABRA2 DRD4 DRD2 CYBB COMT
8 dopaminergic synapse GO:0098691 9.13 SLC6A3 DRD3 DRD2
9 membrane GO:0016020 10.35 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
10 integral component of membrane GO:0016021 10.21 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.91 NPY HTR1B GABRA2 DRD5 DRD4 DBH
2 cellular calcium ion homeostasis GO:0006874 9.88 DRD5 DRD4 DRD3
3 locomotory behavior GO:0007626 9.88 SLC6A3 DRD3 DRD2 DBH
4 memory GO:0007613 9.87 SLC6A4 DBH BDNF
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 NPY HTR1B DRD4
6 learning GO:0007612 9.83 DRD3 COMT BCHE
7 social behavior GO:0035176 9.83 SLC6A4 DRD4 DRD3
8 visual learning GO:0008542 9.82 DRD3 DRD2 DBH
9 neurotransmitter transport GO:0006836 9.81 SLC6A4 SLC6A3 GABRA2
10 feeding behavior GO:0007631 9.78 NPY HTR1B DRD2
11 associative learning GO:0008306 9.77 DRD5 DRD2 DBH
12 negative regulation of blood pressure GO:0045776 9.77 DRD5 DRD3 DRD2
13 arachidonic acid secretion GO:0050482 9.76 DRD4 DRD3 DRD2
14 behavioral response to cocaine GO:0048148 9.74 DRD4 DRD3 DRD2
15 response to nutrient GO:0007584 9.73 SLC6A4 CYBB BCHE
16 synaptic transmission, dopaminergic GO:0001963 9.72 DRD5 DRD3 DRD2
17 response to pain GO:0048265 9.71 DBH COMT
18 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD3 DRD2
19 response to iron ion GO:0010039 9.71 SLC6A3 DRD2
20 vasoconstriction GO:0042310 9.71 SLC6A4 HTR1B
21 negative regulation of protein secretion GO:0050709 9.71 DRD4 DRD3 DRD2
22 response to ethanol GO:0045471 9.71 SLC6A3 HTR1B DRD3 DRD2
23 positive regulation of renal sodium excretion GO:0035815 9.7 DRD3 DRD2
24 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 SLC6A3
25 regulation of postsynaptic neurotransmitter receptor